Weyland Tech’s (WEYL) Partner MOCAAPP Announces Application Sales in the Philippines and Start of Vietnam Marketing

Hong Kong- April 27, 2017- Weyland Tech Inc. (OTCQB: WEYL) (“Weyland” or the “Company”), a provider of mobile business applications, announces initial subscriptions and revenues from its South East Asian partner, MOCAAPP. Marketing and development of additional applications – powered by CreateApp – continues in the Philippines through the Company’s white label channel partner.

According to the Department of Trade and Industry, the Philippines is home to nearly 90,000 Small and Medium businesses (“SMB’s”) and ~900,000 MSMBs (Micro-Small-Medium-sized-Business) overall. Weyland believes that a substantial number of these businesses will ultimately choose to expand their reach through mobile commerce (m-commerce), which has been the case in the US, Europe, and North Asia.

Leong Yew Poh, Chairman of Weyland’s channel partner – MOCAAPP said, “We are pleased with the ease of use and flexibility of the CreateApp platform and are encouraged by the initial marketing efforts in our partnership with Weyland announced in October of last year.

Concurrently, MOCAAPP indicated initial marketing and trade show efforts have begun in Vietnam.

Weyland believes the expansion of m-commerce in South East Asia is in the early stages and is working with their channel partners to become the mobile on-ramp for e-commerce in the region.

For further information about Weyland Tech, Inc., contact Rich Kaiser, Investor Relations, YES INTERNATIONAL 757-306-6090 (001-757-306-6090), yes@yesinternational.cominfo@weyland-tech.com, and http://www.weyland-tech.com/.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements.” The statements regarding the continued growth of the mobile app segment and the ability of the Company to continue its expansion into that segment and the ability of the Company to attract customers and partners and generate revenues. Often these forward-looking statements are identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). Expressly, all forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Predictive Technology Group, Inc. (PRED) Reaches Key Clinical Milestone in Development of Genetic Tests for Infertility and Endometriosis

Development of ARTGuide® Test Will Rapidly Accelerate Short-Term Company Growth

Salt Lake City, UT — (January 18, 2017) – Predictive Therapeutics, LLC, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, was formally notified by its research and development partner, Juneau Biosciences, LLC that a key product development milestone has been reached — the sensitivity and specificity of the ARTGuide® predictive test has passed a critical clinical threshold.  Details of this achievement will remain confidential until a scheduled scientific presentation at the upcoming World Congress of Endometriosis to be held in Vancouver, Canada in May 2017.  Predictive Therapeutics will continue to provide development and financial support to Juneau to allow final validation of these “Laboratory Developed Tests” (LDTs) under “Clinical Laboratory Improvement Amendments” (CLIA) guidelines

In 2016, Predictive Therapeutics signed a license agreement with Juneau Biosciences, LLC for the commercialization of assays and related services for the prediction of Endometriosis, and other health concerns, in the infertility market. This license extends the close relationship between the two companies.

Given these developments, Predictive Therapeutics and Juneau are now poised to launch their novel test for women experiencing infertility, called ARTGuide®. The ARTGuide® Test is expected to change the way that Advanced Reproductive Technologies (ART) such as In Vitro Fertilization (IVF) is used to help couples struggling to have a baby.  The commercial launch of the ARTGuide® infertility test in the United States is now expected during Q3 2017.

Bradley Robinson, PRED CEO states, “I am quite certain that the ARTGuide® Test has the potential to increase the likelihood that couples struggling with infertility will be more successful at becoming pregnant, which could dramatically transform this lucrative infertility market.  The ARTGuide® Test will provide ‘must-have’ information for affected couples and their physicians.

About Endometriosis:

Endometriosis affects more than 10 million women in the United States.  Endometriosis occurs when the tissue similar to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis.  Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life.  Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women with endometriosis suffer for over a decade before receiving treatment.  Treatment may involve hormonal suppression or the targeted destruction of the abnormal tissue during surgery.

About Juneau Biosciences:

Juneau Biosciences is a privately held medical genetics company conducting groundbreaking research to develop innovative diagnostic products for diseases that predominantly affect women. Launched in early 2007, the Salt Lake City, Utah-based firm has focused so far on the development of novel molecular diagnostics and therapeutics for endometriosis, a condition estimated to affect approximately 10% of reproductive-age females. This research is the basis of all the tests and therapies that we will produce, patent, and disseminate to signal the revolution in women’s health care. 
 Over the next several years, Juneau will launch additional programs for preterm labor and other gynecological and obstetric disorders. Juneau expects to improve the lives of millions of women through our genetic research and innovative health care solutions. 

Juneau Biosciences’ knowledgeable team, state-of-the-art facilities, and innovative research techniques give us a unique advantage in developing diagnostics and treatments for women. 

About Predictive Technology Group, Inc.:

Predictive Technology Group, Inc. ( PRED ), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about the release contact, Mr. Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.predictivetechnologygroup.com, www.predrx.com, and www.yesinternational.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

 

Northstar Electronics Recap of Main Events of 2016

Virginia Beach, VA, Jan. 10, 2017 (GLOBE NEWSWIRE) — Northstar Electronics, Inc.(NEIK:OTCQB), the “Company”,  provides a Recap of the main events of 2016.

To summarize, the Company’s primary objectives for 2016 were two fold. One was to improve the Company’s standing as a publicly traded platform. The second was to make significant progress for the Company’s subsidiary, Northstar Sealand Enterprises Ltd. (NSEL), to secure the exclusive worldwide ownership rights to the enhanced version of a single engine Turbo-Prop industrial airplane owned by the subsidiary of a major international aerospace company. NSEL intends to manufacture, market and sell the airplane and also carry out Maintenance, Repair and Overhaul (MRO) services.

During the year, the Company achieved its goals of becoming current with its SEC filings and returning to the OTCQB trading platform, actions fundamental to the Company’s future success.

With respect to the acquisition of the rights to the airplane, significant progress was made on key matters. Agreement with the aerospace company subsidiary was reached during the year on the main technical issues. As well, strong progress was made on project scheduling and cost estimates.

At year’s end, NSEL and the aerospace company subsidiary signed a milestone Memorandum of Understanding (MOU). The MOU outlines the key actions and goals to be reached in order for both parties to implement their business plans going forward. The signing of this MOU is a major step which ultimately should lead to NSEL reaching its manufacturing and marketing objectives within a reasonable time frame.

GOALS FOR 2017

The Company’s goals for NSEL in 2017 are to finalize the acquisition of the exclusive worldwide rights to the Turbo Prop industrial airplane and initiate the transfer of the Type Certificate to NSEL, to initiate the establishment of first order technical support, to put in place a Supply Chain Management system, to initiate the marketing campaign and to secure the first sales orders for the airplane.

We will be approaching institutional investors and venture capital companies for the funding needed to grow the company. As well, we will explore funding opportunities through certain government support programs.

About Northstar Electronics, Inc.

Northstar was established in the late 1990’s. The Company has carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. Since termination of the above contracts Northstar has been seeking other strategic relationships

Safe Harbor Statement:

This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

For further information about this news release contact:

Rich Kaiser, Investor Relations, Yes International, 757-306-6090, yes@yesinternational.com

Predictive Technology Group, Inc. (PRED) Announces Acquisition of US Patent Application for Method for Treating Patients with Stem Cells “Cleaned” via CRISPR

Acquisition Strengthens Commercialization Strategy of Company’s Gene Therapy Products

Salt Lake City, UT — January 10, 2017 – Predictive Technology Group, Inc. (OTCPINK: PRED), a life sciences technology holding company, announced the acquisition of US patent application 62/295,042 direct to the practice of “cleaning” stem cells of a predetermined disease-associated marker via theClustered Regularly Interspaced Short Palindromic Repeats CRISPR” process and administering the stem cells to the patient.

“Clustered Regularly Interspaced Short Palindromic Repeats” (CRISPR) technology offers several advantages over previous forms of gene-editing. The human cell’s genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. Unlike other current practices which involve the introduction of foreign DNA.

“The claims are drawn to the ’cleaning‘ of any stem cell having a predetermined disease associated biomarker,” said Mike Schramm, PRED’s Director of Intellectual Property.  “Because the patent application is for both autologous (withdrawn from and reintroduced to the same patient) and homologous (derived from another source), we see very broad use of the application.”

These rights enable PRED to both diagnose a patient for a genetic disease based on a specific biomarker and subsequently treating the patient with their own stem cells having the diagnosed biomarker eliminated via the CRISPR method.

“This is a significant opportunity for our company to obtain the rights to this invention,” said Bradley Robinson, President and Chief Executive Officer of PRED. “The technology is a strong bridge between our Molecular Diagnostic and Regenerative Medicine product portfolios.”

The global genome editing market is expected to reach USD $5.54 Billion by 2021 from USD $2.84 Billion in 2016, growing at a CAGR of 14.3%. (Source: Market and Market 2016 Genome Editing and Genome Engineering Report)

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com and www.predictivetechnologygroup.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) ANNOUNCES NEW PRESIDENT/CEO /CHAIRMAN

Virginia Beach, VA- January 3, 2017- BioForce Nanosciences Holdings, Inc. (BFNH.OTCPINK) announces Mr. Merle Ferguson as its new President/ CEO / Chairman.  Mr. Ferguson brings to BFNH business acumen from both the public and private business arenas.

Further, BioForce Nanosciences Holdings, Inc.’s business focuses on the acquisition of services, productions, and agricultural facilities within the food services sector.

For further information about this release, contact YES INTERNATIONAL, Investor Relations, 757-306-6090, yes@yesinternational.com and www.yesinternational.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.

NORTHSTAR ELECTRONICS, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH MAJOR AEROSPACE COMPANY

 Virginia Beach, VA– December 20, 2016- Northstar Electronics, Inc.,(OTCQB:NEIK), the “Company” is pleased to announce that it has signed a Memorandum of Understanding (MOU) with a subsidiary of a major international Aerospace Company.

Northstar Electronics’ subsidiary, Northstar Sealand Enterprises Ltd (NSEL), has the objective of acquiring the exclusive world-wide rights to an enhanced version of a single engine Turbo-Prop industrial airplane from the subsidiary of the international aerospace company.

NSEL would manufacture, market and sell the airplanes and also carry out Maintenance, Repair and Overhaul (MRO). The MOU outlines key actions and goals to be reached in order to implement this new business plan for the Company.

The signing of this MOU is a first step which ultimately should lead to NSEL reaching its manufacturing and marketing goals within a reasonable time period.  As part of the overall new focus of the Company, NSEL would also implement a strong marketing and sales campaign to maximize early orders for the new version of the airplane.

As more information becomes available and further developments occur between Northstar Electronics and the Aerospace Company, shareholders and other interested parties will be promptly notified on the progress in accordance with guidelines and requirements indicative for publicly traded companies.

For further information about this news release contact:

Rich Kaiser, Investor Relations, Yes International, 757-306-6090, yes@yesinternational.com

 

About Northstar Electronics, Inc.

Northstar was established in the late 1990’s. The Company has carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. Since termination of the above contracts Northstar has been seeking other strategic relationships

Safe Harbor Statement:

This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

Predictive Technology Group, Inc. (PRED) Retains Stevenson & Company CPAs

Stevenson & Company CPAs will act as independent auditors of Predictive Technology Group, Inc.

Salt Lake City, UT — (December 20, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announces the Company has retained Stevenson & Company CPAs as its PCAOB auditing firm.

Stevenson & Company CPAs will act as independent auditors as required to become a fully reporting company under US SEC rules.

Upon completion of the audited financial statements and other legal narratives required to become fully reporting, The Company will transmit its registration statement to the US SEC for approval.

For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com and www.predictivetechnologygroup.com.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future. The Company does not undertake any obligation to provide an update with respect to any potential legal or financial transactions, except as required under the applicable law.

 

 

Bravo Multinational Incorporated (BRVO) – Update  

Toronto, Canada – December 19th, 2016- Bravo Multinational Incorporated (OTCQB: BRVO) reports on Company activities.

10Q for Quarter ending September 30, 2016:

The Company would like first to apologize to its shareholders for the yet to be filed “Quarterly Report.” The cause of this extensive delay is due to serious ongoing health issues with BRVO’s CFO. That being said, after numerous interviews with several firms over the past few weeks, the Company has on Friday, December 16, 2016, finalized the engagement of a new accounting firm that will immediately take over the full accounting duties of the Company. This new firm located in New York State has extensive US SEC accounting experience.  Management welcomes the new addition to the Bravo team. The Company’s PCAOB auditing firm, Scrudato & Co., PA-Certified Public Accounting Firm, has not changed.

El Salvador- Central America:

The gaming license operational openings in municipalities in the capital city of San Salvador, El Salvador will be delayed due to current circumstances out of the Company’s control. The parties that were to fund and open the two locations have decided to hold off on the location openings. Bravo’s management has worked with the El Salvadoran associates for the past year to plan this new business venture and hope to have the licenses put to work, shortly.

Equipment Sales:

BRVO sales division for gaming equipment reports that Q4 is moving well within anticipated projections.  Management looks forward to furthering future sales growth going into, and throughout 2017.

OTCQB Status:

The Company has had many inquiries regarding the Company’s OTCQB status due to the late filing and the sub-penny share price. The OTCQB status will be maintained and immediately regained as soon as the filings are up- to- date.  As for the share price, the Company has six months to regain a level of one cent (0.01) to maintain the OTCQB status.

 

Market Stock Selling/buying:

Recently, the Company is aware of certain large shareholders (non-affiliates) that have informed the Company that they have chosen to divest in Bravo at this time to take advantage of year-end tax planning, as well as, to move on to alternate investments. This trading activity resulted in more than 15 million shares being put onto the open market, recently.  Before this occurring, the last couple of weeks the Company feels that significant short selling pressure started in mid-September, adding to the share price declines. The Company has no control over free-trading share sales.

Core Business Focus:

BRVO continues its positive efforts to increase revenues and intends to grow the core gaming equipment business throughout next year and bring forth a strong balance sheet for 2017.  Q4 2016 should report positive sales growth. Additionally, the company has made arrangements to enhance its equipment sales operation, by opening an independent Bravo sales office in the New Year.   Regardless of the current share price, the core business is growing, and BRVO anticipates extensive growth throughout 2017.

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCQB: BRVO) is a diversified Company, with its main focus on the development and expansion of the Casino Gaming Equipment holdings and Gaming related business activities throughout Central and South America. Bravo’s growth strategy, driven by partnerships, acquisitions, and new ventures should result in financially viable and profitable corporate divisions.

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

 

Predictive Technology Group, Inc. (PRED) Announces Notice of US Patent Allowance for Method for Treating Patients with Genetic Spinal Deformities and Syndromes

Allowance Strengthens Commercialization Strategy of Company’s Proprietary Diagnostics and Therapeutics

Salt Lake City, UT — (December 16, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a fundamental patent application – US20160296671 -that covers the practice of administering “ANY” spine deformation therapeutics to a patient having a spine deformation altered risk associated biomarker.

“We are pleased to see this latest allowance that supports PRED’s novel approach to diagnosing spinal disorders and syndromes, “said Mike Schramm, PRED’s Director of Intellectual Property. “This allowed US patent application supports the commercial use of both our diagnostic and next-generation companion treatment products.”

The claims of the ‘671 application build on previously issued US patents 8,123,787, 8,641,738, and 9,370,431 to which ‘671 claims priority and further bolster Predictive Technology Group’s Intellectually Property position.

“We are gratified to see this latest application allowance, which covers the core technology underlying the Company’s molecular diagnostic test” said Bradley Robinson, President and Chief Executive Officer of Predictive Technology Group, Inc. “Furthermore, this fundamental patent covers not only spinal applications of our technology but establishes a precedent for the other patent applications that have been submitted on the Company’s portfolio of next-generation diagnostic and companion treatment products.”

The allowance of this new application is a significant milestone for Predictive Technology Group.  The patent establishes the foundation of key intellectual property (IP) covering ANY treatment options (drug, surgery, bracing, etc.) for patients having a specific spine deformity biomarker.  This newly allowed application is additive to previously announced patents.  Furthermore, the Company has additional US and International patent applications pending and will pursue such applications with the objective of receiving additional issued patents in additional disease states.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases, www.predictivetechnologygroup.com

For more information about PRED, contact Mr. Richard Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Weyland Tech (WEYL) Enters Into Strategic Partnership with Express & E-Commerce Solutions Provider

Hong Kong —December 6, 2016 — Weyland Tech Inc. (OTCQB: WEYL) (“Weyland Tech” or the “Company”), a provider of mobile business applications, announces that it has entered into a Strategic Partnership with DPEX Worldwide, a leading provider of express and E-Commerce solutions in Asia.

DPEX Worldwide in collaboration with WEYL will together offer a Mobile Commerce (“m-commerce”) solution coupled to a logistics solution. This will provide users subscribing to the application with a one-stop end-to-end solution incorporating m-commerce setup and operation, payment gateways for m-commerce transactions, logistics services such as warehousing, fulfillment, cross border and domestic distribution.

About Weyland Tech Inc.

Weyland Tech’s “CreateApp” platform is focused on the Asia markets. Our CreateApp platform is offered in 12 languages and enables small-medium-sized businesses (“SMB’s”) to create a mobile application (“APP”) without the need of technical knowledge and background. SMB’s can increase sales, reach more customers and promote their products and services via a simple easy to build mobile APPs in an affordable and cost-effective manner, www.weyland-tech.com.

About DPEX Worldwide

DPEX Worldwide is an established Express and E-Commerce solutions provider in Asia providing a wide array of solutions and services catering to the growing need for seamless end to end logistics requirements by customers today.

With a history and experience dating 30 years and a comprehensive network spanning 17 countries in the region, DPEX Worldwide has extensive local knowledge to serve into and throughout Asia.

DPEX Worldwide is widely acknowledged as “Knowing Asia, Delivering Asia.” From Asia to the world, DPEX Worldwide is positioned and poised to be a leading total solutions provider in the region, able to cater to the requirements for both cross border and domestic logistics solutions.

For further information about Weyland Tech, Inc., contact Rich Kaiser, Investor Relations, YES INTERNATIONAL 757-306-6090 (001-757-306-6090), yes@yesinternational.com,info@weyland-tech.com and http://www.weyland-tech.com.

Safe Harbor Statement
This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.